Home Uncategorized

Uncategorized

Calicheamicin

Calicheamicin was discovered in the 1980s by a scientist from Lederle Laboratories (now Pfizer) while on vacation in Texas. The...

Collagen-VI-Alpha-1 is a New Target and a Marker of Poor Outcome in Glioblastoma

Functional targeted therapy has unfortunately failed to improve the outcome of glioblastoma patients. While success stories evidenced by the...

First Bispecific FynomAb® for Preclinical Development Nominated

Covagen, a privately owned Swiss company developing bispecific FynomAbs by fusing its human Fynomer binding proteins to antibodies, resulting...

CytomX’s Antibody Therapies Target Cancer, Leave Healthy Tissue Intact

Antibody technology holds promise for treating a wide array of diseases, and designing new antibodies is a hot area...